Search
Search results
818 results found
Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.
Poewe, W, RA Hauser, and A Lang. 2015. “Effects of Rasagiline on the Progression of Nonmotor Scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.”. Mov Disord.
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.
Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.
Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 2016;33:127-133.
Wills, AA, JJ Elm, R Ye, KL Chou, SA Parashos, RA Hauser, I Bodis-Wollner, et al. 2016. “Cognitive Function in 1736 Participants in NINDS Exploratory Trials in PD Long-Term Study-1. Parkinsonism Relat Disord 2016;33:127-133.”. Parkinsonism Relat Disord.
Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.
Hauser, RA, MF Gordon, Y Mizuno, W Poewe, P Barone, AH Schapira, O Rascol, C Debieuvre, and M Fradorf. 2014. “Minimal Clinically Important Difference in Parkinson’s Disease As Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.”. Parkinsons Dis.
Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80.
Goldman, SM, F Kamel, GW Ross, SA Jewell, C Marras, JA Hoppin, DM Umbach, et al. 2014. “Peptidoglycan Recognition Protein Genes and Risk of Parkinson’s Disease. Mov Disord 2014;29:1171-80.”. Mov Disord.
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13:767-76.
Hauser, RA, CW Olanow, KD Kieburtz, E Pourcher, A Docu-Axelerad, M Lew, O Kozyolkin, et al. 2014. “Tozadenant (SYN115) in Patients With Parkinson’s Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol 2014;13:767-76.”. Lancet Neurol.
Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.
Bajaj, N, RA Hauser, J Seibyl, A Kupsch, M Plotkin, C Chen, and ID Grachev. 2014. “Association Between Hoehn and Yahr, Mini-Mental State Examination, Age, and Clinical Syndrome Predominance and Diagnostic Effectiveness of Ioflupane I 123 Injection (DaTSCAN™) in Subjects With Clinically Uncertain Parkinsonian Syndromes.”. Alzheimers Res Ther.
Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-6.
Goetz, CG, GT Stebbins, KA Chung, RA Hauser, JM Miyasaki, AP Nicholas, W Poewe, et al. 2013. “Which Dyskinesia Scale Best Detects Treatment Response? Mov Disord 2013;28:341-6.”. Mov Disord.
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017;89:1959-1969.
Mollenhauer, B, CJ Caspell-Garcia, CS Coffey, P Taylor, LM Shaw, JQ Trojanowski, A Singleton, et al. 2017. “Longitudinal CSF Biomarkers in Patients With Early Parkinson Disease and Healthy Controls. Neurology 2017;89:1959-1969.”. Neurology.